NewTimeSpace News: August 03, 2026, L & M CHEMICAL(00746.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at HKD 2.17 billion, increased by 12.23% YoY
NewTimeSpace (newtimespace.com) reported that on August 3, 2026, the chip theme weakened, with SMIC (00981.HK) fluctuating lower. As of 13:20, the stock was quoted at HKD 61.900, down 2.13%.
NewTimeSpace News: Metis TechBio Co., Ltd. (07666.HK) announced a collaboration with HENGRUI PHARMA for the localized deployment of its AiTEM AI formulation platform at Hengrui. Driven by the Company's proprietary NanoForge nano-delivery engine, the platform has previously shortened the formulation optimization cycle from 1–2 years to just 3 months. The Company, which went public in May 2026, is recognized as the "world's first AI-powered drug delivery public company."
NewTimeSpace (newtimespace.com) reported that on August 3, 2026, the robotics theme strengthened, with UBTECH (09880.HK) fluctuating higher. As of 13:12, the stock was quoted at HKD 84.050, up 3.07%.
NewTimeSpace News: Shoucheng Holdings Limited (00697.HK) announced that a fund managed by a company under its Shoucheng Capital arm has invested in Hefei Mezheng Quantum Technology Co., Ltd. Mezheng Quantum is a leading domestic enterprise in QCCD ion trap quantum computing. This investment will drive the company's core technology R&D and industrialization efforts.
NewTimeSpace (newtimespace.com) News, August 02, 2026, JUFEEL(08611.HK) released its Interim Report for the period ended November 30, 2026, Total Revenue stood at MYR 12.96 million, decreased by 2.01% YoY
NewTimeSpace (newtimespace.com) News, July 31, 2026, FERRETTI(09638.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at EUR 635.23 million, decreased by 6.17% YoY
NewTimeSpace News: InSilico Medicine announced that its oral NLRP3 inhibitor ISM8969/HT-001, co-developed with Hengtai Bio and empowered by the generative AI platform Chemistry42, received NMPA IND approval for Parkinson's disease treatment, marking the formal launch of parallel clinical evaluations in China and Australia; the blood-brain barrier-penetrating candidate achieved PCC nomination in December 2024, FDA IND approval in January 2026, first human dosing in Australia in June 2026, and NMPA IND approval in July 2026.
NewTimeSpace News: AIM Vaccine announced that its wholly-owned subsidiary AIM Honor has completed supplementary data submission to the CDE for its serum-free iterative rabies vaccine (CXSS2500044) following successful on-site inspections, with Phase III results demonstrating good safety, immunogenicity, and immune persistence; the vaccine eliminates animal serum components to significantly reduce adverse reaction rates; the China rabies vaccine market is expected to reach RMB 14.8 billion by 2030, and the group has completed international-standard facility construction and commercial-scale validation production.
NewTimeSpace News: Ascentage Pharma announced the appointments of Dr. Faïçal Miyara as CBO and Jim Ziegler as CCO, both reporting directly to Chairman and CEO Dr. Yang Dajun; Dr. Miyara brings over 20 years of oncology BD experience from Pfizer, Ipsen, and IO Biotech with involvement in FDA-approved drugs including Erbitux® and Cyramza®, while Mr. Ziegler brings over 25 years of commercial operations experience from Amgen, Gilead Sciences, Lovance Biotherapeutics, and Geron.
NewTimeSpace News: Geely Automobile announced July 2026 total sales of 250,161 units (up 5% YoY), with cumulative Jan-Jul sales of 1,673,119 units (up 2% YoY); Zeekr led growth with 35,837 units (up 111% YoY), while Lynk & Co declined 40% to 16,382 units; BEV sales rose 17% to 105,365 units, PHEV sales climbed 37% to 54,800 units, and exports surged 202% to 106,663 units; Proton contributed 19,599 units (up 39% YoY); all figures remain unaudited.
NewTimeSpace News: Momenta announced the end of the stabilization period on 2 August 2026, during which the stabilization manager over-allotted approximately 15% (2,990,740 shares) of the global offering, borrowed an equivalent number of shares from lenders, and subsequently purchased 2,990,740 shares in the market at prices between HKD 242.20 and HKD 295.60 to return the borrowed shares; the over-allotment option lapsed unexercised, with no additional shares to be issued.
NewTimeSpace News: Voyah announced July 2026 deliveries of 13,189 vehicles (up 9% YoY) and cumulative deliveries of 89,453 vehicles (up 31% YoY); the all-new Voyah Dreamer 9 MPV is planned for H2 2026 launch in the RMB 500,000 segment, the Voyah Pursuit S opens for pre-order ahead of its 15 August launch, and the self-developed "Voyah Huju Intelligent Chassis" was officially named.
NewTimeSpace News: BYD announced July 2026 NEV production of 420,249 units and sales of 419,211 units, including 233,105 pure electric and 177,967 plug-in hybrid passenger vehicles; cumulative NEV sales for the year reached 2,227,722 units (down 10.54% YoY), with July exports totaling 180,538 units; all figures remain unaudited.
NewTimeSpace News: MicroPort CardioFlow announced that its wholly-owned subsidiaries entered into two five-year lease agreements on 31 July 2026: Shanghai MicroPort CardioFlow will lease Property I (approx. 9,042 sqm) for heart valve production at total rent of RMB 90.76 million with right-of-use assets of RMB 78.47 million; CardioLead Rhythm will lease Property II (approx. 4,635 sqm) for cardiac rhythm management production at total rent of RMB 46.52 million with right-of-use assets of RMB 40.23 million
NewTimeSpace News: LeadsBiolabs announced that its self-developed WeilixinTM (PD-L1/4-1BB bispecific antibody opatisumab, LBL-024) received CDE IND approval for metastatic colorectal cancer (mCRC) to initiate an open-label, multi-center Phase Ib/II study; the drug simultaneously blocks the PD-1/PD-L1 pathway and conditionally activates the 4-1BB pathway, with prior clinical activity validated across EP-NEC, NSCLC, SCLC, and BTC; the company has launched 13 solid tumor indication studies in China, and WeilixinTM, as the world's first 4-1BB-targeting molecule in pivotal single-arm registrational trials, has received CDE Breakthrough Therapy, FDA Orphan Drug, and Fast Track designations.
